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Abstract
Objectives The neutrophil–lymphocyte ratio (NLR) is an inlammatory biomarker which is useful in cancer prognostication. 
We aimed to investigate the diferences in baseline NLR between patients with localised and metastatic cutaneous melanoma 
and how this biomarker changed over time with the recurrence of disease.
Methods This multicentre cohort study describes patients treated for Stage I–III cutaneous melanoma over 10 years. The 
baseline NLR was measured immediately prior to surgery and again at the time of discharge or disease recurrence. The odds 
ratios (OR) for sentinel node involvement are estimated using mixed-efects logistic regression. The risk of recurrence is 
estimated using multivariable Cox regression.
Results Overall 1489 individuals were included. The mean baseline NLR was higher in patients with palpable nodal disease 
compared to those with microscopic nodal or localised disease (2.8 versus 2.4 and 2.3, respectively; p < 0.001). A baseline 
NLR ≥ 2.3 was associated with 30% higher odds of microscopic metastatic melanoma in the sentinel lymph node [adjusted 
OR 1.3 (95% CI 1.3, 1.3)]. Following surgery, 253 patients (18.7%) developed recurrent melanoma during surveillance 
although there was no statistically signiicant association between the baseline NLR and the risk of recurrence [adjusted 
HR 0.9 (0.7, 1.1)].
Conclusion The NLR is associated with the volume of melanoma at presentation and may predict occult sentinel lymph 
metastases. Further prospective work is required to investigate how NLR may be modelled against other clinicopathological 
variables to predict outcomes and to understand the temporal changes in NLR following surgery for melanoma.
Keywords Neutrophil–lymphocyte ratio · Platelet–lymphocyte ratio · Lymphocyte–monocyte ratio · Cutaneous melanoma · 
Recurrence · Biomarker
Abbreviations
CI  Conidence interval
FBC  Full blood count
HR  Hazard ratio
IQR  Interquartile range
NLR  Neutrophil lymphocyte ratio
OR  Odds ratio
SLN  Sentinel lymph node
WLE  Wider local excision
Introduction
The incidence of melanoma has risen faster than any other 
cancer worldwide [1, 2] and the status of the sentinel lymph 
node (SLN) is the single most important prognostic factor 
[3]. Whilst there are several algorithms for predicting metas-
tases of melanoma to the SLN [4–10] their external validity 
is weak [4, 11–14]. Consequently, only 1 in 5 patients under-
going SLN biopsy yield a node with microscopic deposits 
[15]. SLN biopsy for melanoma carries an 11% risk of com-
plication [16] and recent trials [17, 18] suggest no additional 
Derivations of this work were presented at the triennial World 
Melanoma Congress (Brisbane, Australia; 2017); the Canadian 
Society of Surgical Oncology Annual Symposium (Vancouver 
Island, Canada; 2017 [56]); the British Association of Plastic, 
Reconstructive and Aesthetic Surgeons Winter Meeting (London, 
UK; 2017); the International Pigmented Cell Congress (Denver, 
USA; 2017); the European Association of Dermato-Oncology 
International Congress (Athens, 2017 [57]) and Melanoma 
FOCUS (Newcastle 2017, UK).
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survival beneit from completion lymphadenectomy. There-
fore, whilst staging the draining nodal basin remains an 
important goal, there is a pressing need to improve patient 
selection and avoid unnecessary SLN biopsies which might 
be achieved using host biomarkers [19].
For surgically resected BRAF V600-positive Stage III 
melanoma, adjuvant dabrafenib and trametinib improves 
survival, although discontinuation due to adverse efects is 
common (25%) [20]. Further, adjuvant treatment for non-
BRAF-mutated tumours improves survival but again, 15% 
experience drug-related adverse efects and rarely, prema-
ture-death [21]. Therefore, it may be desirable to reine the 
selection of patients for adjuvant therapy to those at the 
highest risk of recurrence.
With recent advances in adjuvant therapy [22] and a ris-
ing incidence, the number of patients living with melanoma 
has dramatically increased. In light of the indings of the 
Multicentre Selective Lymphadenectomy Trial (MSLT-II) 
trial [19] yet more patients will be subject to surveillance 
rather than up-front lymphadenectomy. Therefore, early 
detection of recurrent disease is desirable as systemic ther-
apies are more eicacious in patients with a lower disease 
burden [23]. Hence, there is an unmet need for a cheap, 
simple and reliable biomarker to augment the selection of 
patients for SLN biopsy and adjuvant therapy, and to aid in 
the surveillance of patients with melanoma.
In response to malignancy and for reasons that are not 
yet fully elucidated, the host induces a myeloid immune 
response (manifesting as neutrophilia and thrombocytosis) 
whilst suppressing the adaptive immune (lymphoid) lineage; 
paradoxically, this favours tumour growth, angiogenesis, and 
regional and distant metastasis [24, 25]. This inlamma-
tory response is manifested in the peripheral blood neutro-
phil–lymphocyte ratio (NLR) [26–29], which has become an 
established biomarker of systemic inlammation and various 
outcomes in numerous cancers [30–32]. Further, the NLR 
has a strong association with survival in melanoma [33–39]. 
Currently, there is a gap in the literature concerning the rela-
tionship between NLR and outcomes in locoregional mela-
noma, the most prevalent form of the disease, which formed 
the rationale for this study.
Methods
Study design and patients
This is a multicentre cohort study of patients with locore-
gional melanoma who underwent surgery with cura-
tive intent between 2006 and 2016 in Yorkshire and the 
East of England, UK. A secure electronic database was 
prospectively completed and retrospectively augmented 
with blood test data from the hospitals’ electronic systems.
Eligibility criteria
We included patients with a biopsy-proven primary cuta-
neous melanoma who underwent surgery (wide excision 
and sentinel lymph node biopsy or lymphadenectomy). 
Patients were excluded if no full blood count (FBC) was 
recorded at baseline. Patients were also excluded for any 
of the following reasons which are known to afect the 
NLR: another concurrent malignancy, active infection, 
pregnancy, chronic inlammatory conditions, proliferative 
haematopoietic disorders, pharmacological immunosup-
pression, multiple or occult primary melanoma, recurrent 
melanoma, unidentiiable or unclassiiable tumours.
Variables
All histopathological features of the primary tumour were 
recorded and updated following wider re-excision. We 
used the FBC obtained after excision biopsy but before 
surgery with curative intent (i.e. WLE and SLN biopsy or 
lymphadenectomy) to compute the baseline NLR (abso-
lute neutrophil ÷ absolute lymphocyte count). The plate-
let–lymphocyte and lymphocyte–monocyte ratios (PLR 
and LMR, respectively) were calculated likewise. If there 
were multiple blood tests acquired in this period, we used 
the result closest to the deinitive surgery. In a nested 
cohort, the last available FBC (up to 28 days prior to the 
diagnosis of recurrence or discharge) was used to calculate 
changes in blood counts and their ratios over time.
Outcomes
The primary outcome was the association between NLR 
and occult metastatic melanoma in the SLN, identiied 
by histopathological assessment. Secondary outcomes 
included: (1) diferences in the baseline NLR between 
localised, microscopic metastatic and macroscopic disease 
presentations; and (2) the changes in NLR for those who 
developed recurrent melanoma detected clinically, radio-
logically and/or by cellular techniques (histopathological 
assessment of a biopsy with immunohistochemistry or 
cytological assessment of ine needle aspirates). Patients 
disease-free at discharge or lost to follow-up were cen-
sored. The time to recurrence was calculated from the date 
of deinitive surgery (SLN biopsy or lymphadenectomy) to 
the date of the multidisciplinary team diagnosis of recur-
rent melanoma.
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Statistics
There was no literature on which to base a power calcu-
lation, so this was hypothesis generating research. Data 
were analysed using Stata v15. Blood counts (and ratios) 
were skewed but lognormal, so are summarised by the 
geometric mean and compared using t-based methods. The 
threshold for NLR (2.3) was informed by previous work 
[34, 37–39] and selected based on the optimum Harrell 
C-statistic and assessment of restricted cubic splines. The 
association between NLR and the odds ratio (OR) for SLN 
metastasis was estimated using multilevel (mixed-efects) 
logistic regression, with random-efects carrying by the 
hospital, i.e. cluster. The risk of recurrence (hazard ratios, 
HR) was estimated using multivariable Cox regression. 
All covariables were selected a priori as per our protocol 
[6, 40–49]. Models were internally validated by lossless 
non-parametric bootstrapping by resampling with replace-
ment, with 1000 iterations [50]. Conidence intervals (CI) 
are generated to the 95% level. The family-wise error rate 
was revised down according to Šidák to p < 0.001.
Results
After per-protocol exclusions, data were available for 1489 
of 2438 eligible patients at baseline and a nested cohort 
of 235 individuals had repeated blood data for testing 
(Fig. 1).
Disease status at presentation
Table 1 shows the baseline characteristics for those with 
localised melanoma (SLN biopsy negative), microscopic 
metastatic melanoma (SLN biopsy positive) and those who 
underwent therapeutic lymphadenectomy for palpable/mac-
roscopic metastatic disease at presentation. There were no 
unexpected baseline diferences between groups, except that 
our yield of positive SLN biopsies was higher than expected 
at 25%.
Peripheral blood biomarkers at presentation
The median time from blood test to surgery (either SLN 
biopsy or therapeutic lymphadenectomy) was 19 days (IQR 
3, 28). Table 2 and Fig. 2 show that at presentation, the mean 
NLR was signiicantly higher in patients with palpable nodal 
disease [mean diference 0.2 (95% CI 0.1, 0.3), p < 0.001; 
Fig. 2] compared to others. The baseline NLR was also sig-
niicantly higher in patients with microscopic metastatic 
melanoma in the SLN compared to those with a negative 
SLN biopsy, i.e. localised disease only [mean diference 0.1 
(95% CI 0.1, 0.2), p = 0.02; Fig. 2].
Table 3 shows a strong univariable association between 
NLR and the risk of microscopic metastatic melanoma in the 
SLN. As a crude continuous predictor, the odds of metastatic 
disease in the SLN appeared to increase by 12% per unit rise 
in NLR [OR 1.2 (95% CI 0.1, 1.2), p = 0.03], compared to 
those with a localised disease. At a threshold of NLR ≥ 2.3 
there was a statistically signiicant association between a 
raised NLR and microscopic metastatic melanoma in the 
SLN, whereby a NLR ≥ 2.3 increased the odds of metastasis 
by 30%. Resampling did not change these estimates [boot-
strapped adjusted OR 1.3 (95% 1.2, 1.4), p < 0.001].
Change in NLR over time
The median follow-up was 3.6 years (IQR 2, 6 years; range 
3 months to 10 years). During follow-up 253 patients (19%) 
developed recurrent melanoma which included 16 (13%) 
local recurrences, 44 (35%) nodal recurrence and 66 (52%) 
distant metastases; in the remaining cases the precise loca-
tion of the recurrence was unclear.
Repeat (paired) blood data were available for a nested 
cohort of 235 individuals, all of whom had undergone 
SLN biopsy (80 positive, 155 negative). In this nested 
cohort, 86 (37%) developed recurrence after a median of 
50 months (IQR 26, 75). The remaining 149 individuals 
were disease-free at discharge after a median surveillance 
of 75 months (IQR 52, 113). Table 2 shows no statisti-
cally significant difference in peripheral blood cell counts 
or their ratios, between those who developed recurrence 
and those who were disease-free at discharge. Further, in Fig. 1  Participant low diagram
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those who developed recurrence, there was no statistically 
significant change in peripheral blood cell counts or their 
ratios from baseline to the onset of recurrence.
Baseline NLR and the risk of recurrence
Table 4 shows that the NLR was not significantly associ-
ated with the risk of recurrence in either univariable [HR 
1.1 (95% CI 1.0, 1.2)] or multivariable [adjusted HR 0.9 
(95% CI 0.7, 1.1)] models, which is summarised by the 
Kaplan–Meier plot in Fig. 3. The only variable which 
predicted disease recurrence was SLN positivity which 
increased the risk of relapse fivefold. Re-sampling did 
not change these estimates. 
Discussion
This study suggests that the neutrophil–lymphocyte ratio 
(NLR) is proportional to the volume of cutaneous mel-
anoma at presentation. This inding supports the wider 
literature on other cancers which infers that the NLR rep-
resents the host response to malignancy and thus, is a reli-
able and personalised biomarker.
There are three published works concerning the NLR 
and lymph node metastases of melanoma [34, 37, 38], 
all of which agree with our indings that a raised NLR 
is associated with occult metastatic disease. Gandini 
et al. [34] compared absolute blood counts between SLN 
biopsy positive and negative individuals using rank-based 
Table 1  Baseline characteristics comparing those disease-free (or censored) at inal follow-up and those who developed recurrent melanoma
a As we have arbitrarily grouped this data a test of proportion would not be informative
Localised disease (SLN 
negative, n = 1077)
Microscopic metastases 
(SLN positive, n = 274)
Palpable disease (lym-
phadenectomy, n = 138)
p value
Mean age in years (SD) 63 (13) 60 (14) 65 (17) 0.004
Sex (%)
 Male 542 (50) 136 (50) 70 (51) 0.9
 Female 535 (50) 138 (50) 68 (49)
Median Breslow thickness (mm, IQR) 1.8 (1.2, 3) 2.2 (1.5, 3.5) 2.5 (1.4, 4.5) 0.001
Median Mitoses  mm−2 (IQR) 3 (1, 7) 4 (2, 9) 7 (2, 14) 0.001
Median maximum diameter in mm (IQR) 10 (7, 14) 12 (8, 16) 12 (9, 20) 0.007
Ulceration (%) 251 (25) 72 (28) 52 (42) < 0.001
Angiolymphatic invasion (%) 14 (3) 19 (12) 16 (20) < 0.001
Perineural invasion (%) 17 (4) 7 (5) 2 (4) 0.9
Regression (%) 71 (17) 22 (14) 19 (23) 0.2
Microsatellites (%) 15 (4) 14 (9) 14 (25) < 0.001
Tumour-iniltrating lymphocytes (%)
 Absent 59 (14) 33 (22) 20 (24) 0.001
 Non-brisk 268 (65) 106 (70) 51 (61)
 Brisk 86 (21) 12 (8) 12 (15)
Vertical growth phase (%) 382 (96) 142 (99) 70 (100) 0.04
Pathological subtype (%)
 Nodular 98 (9) 26 (10) 39 (28) n/aa
 Supericial spreading 305 (28) 104 (38) 47 (37)
 Acral 14 (12) 8 (2) 10 (7)
 Other 660 (61) 136 (50) 42 (25)
Residual melanoma in wider re-excision (%) 51 (12) 23 (15) 25 (38) < 0.001
Extracapsular spread (%) n/a 16 (12) 66 (48) < 0.001
Number of involved lymph nodes (%)
 1 n/a 81 93 n/aa
 2 21 66
 3 3 28
 ≥ 4 1 92
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methods and found no evidence of a diference; but when 
modelled against disease progression using Cox regression 
(from Stage I/II to III, i.e. when melanoma metastasises), a 
raised NLR was strongly predictive. This agrees with our 
data whereby the crude blood counts were not diferent 
between groups and highlights the power of ratios which 
magnify smaller diferences to appreciable levels.
Lino-Silva and colleagues [38] showed that a NLR > 2 
was associated with nodal metastasis; however, their study 
concerned acral lentiginous melanoma in the Mexican 
population which is a biologically distinct tumour and 
population, respectively. This reduces the generalisability 
to the majority of afected individuals who are Caucasian 
with nodular or supericial spreading melanoma [51]. The 
proportional analysis by Davis et al. [37] showed that the 
baseline NLR was higher in patients with a more advanced 
nodal substage and thicker tumours. However, they found 
no signiicant diference in the NLR between patients with 
macroscopic and microscopic metastatic melanoma [37]. 
Overall, our indings agree with the literature and sug-
gest that a raised baseline NLR is associated with occult 
metastatic melanoma. Previous works investigated NLR 
incidentally or as a secondary outcome of interest [34, 
37, 38] whereas this study adds an important dimension 
to the literature because the biomarker was of primary 
interest, analysed in a comprehensive fashion and adjusted 
for potential confounding variables. None-the-less, we 
feel that further prospective research is needed to miti-
gate biases of selection and information before the NLR 
is utilised in the management of patients with locoregional 
melanoma.
Table 2  Blood values at disease presentation and inal follow-up
SLN sentinel lymph node
a Derived from linear regression of lognormal data
Geometric means (95% CI)
Leucocytes Neutrophils Lymphocytes Monocytes Platelets Neutrophil–
lymphocyte 
ratio (NLR)
Platelet–lym-
phocyte ratio 
(PLR)
Lymphocyte–
monocyte ratio 
(LMR)
Disease status at presentation
 Localised 
(SLN nega-
tive)
7.2 (7.0, 7.3) 4.4 (4.3, 4.6 1.9 (1.8, 1.9) 0.4 (0.4, 0.4) 252 (246, 258) 2.3 (1.8, 3.1) 132 (130, 140) 4.6 (4.5, 4.8)
 Microscopic 
metastases 
(SLN posi-
tive)
7.3 (6.9, 7.7) 4.6 (4.3, 4.8) 1.8 (1.7, 1.9) 0.4 (0.4, 0.5) 249 (239, 259) 2.4 (1.8, 3.3) 137 (129, 146) 4.3 (4.0, 4.6)
 Palpable 
disease 
(lymphad-
enectomy)
7.4 (7.1, 7.8) 4.7 (4.5, 5.1) 1.7, (1.6, 1.8) 0.4 (0.4, 0.4) 255 (244, 266) 2.8 (2.0, 3.7) 153 (142, 165) 4.0 (3.7, 4.4)
 p  valuea 0.4 0.09 0.003 0.3 0.7 < 0.001 0.003 0.001
Disease status at inal follow-up
 Disease free 
(discharged)
7.1 (6.7, 7.6) 4.2 (4.0, 4.5) 1.8 (1.7, 1.9) 0.4 (0.4, 0.4) 243 (234, 253) 2.4 (2.2, 2.6) 138 (130, 146) 4.5 (4.2, 4.8)
 Recurrent 
melanoma
6.8 (6.4, 7.3) 4.1 (3.8, 4.5) 1.7 (1.6, 1.9) 0.4 (0.4, 0.4) 241 (227, 256) 2.4 (2.1, 2.6) 139 (127, 151) 4.3 (3.9, 4.7)
 p  valuea 0.4 0.5 0.8 0.5 0.8 0.9 0.9 0.4
Fig. 2  The mean logNLR (95% CI) for each group, based on disease 
volume at presentation. Groups were compared by ANOVA with 
Bonferroni correction. The logNLR is the natural logarithm of the 
NLR
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There is a wealth of data on haematological biomarkers 
in metastatic melanoma, which show that a raised baseline 
NLR is associated with almost twice the risk of recurrence 
following systemic therapy [HR 1.86 (95% CI 1.2, 2.8)] [52]; 
Table 3  Odds of occult sentinel 
lymph node metastasis 
CI conidence interval, OR odds ratio, TILs tumour-iniltrating lymphocytes
a Mixed-efects logistic regression with random-efects varying by the hospital cluster
Univariable OR 
(95% CI)
p value Adjusteda OR (95% CI) p value
NLR ≥ 2.3 1.2 (0.9, 1.6) 0.3 1.3 (1.3, 1.3) < 0.001
Angiolymphatic invasion 4.1 (2.0, 8.4) < 0.001 3.5 (1.9, 6.2) < 0.001
Microsatellites 2.8 (1.3, 5.9) 0.008 1.7 (1.4, 2.0) < 0.001
Mitoses per  mm2 1.0 (1.0, 1.1) 0.001 1.1 (1.1, 1.1) < 0.001
Breslow thickness (mm) 1.1 (1.1, 1.2) < 0.001 1.1 (1.1, 1.2) < 0.001
Age in years 1.0 (1.0, 1.0) 0.010 1.0 (1.0, 1.0) < 0.001
Male 1.0 (0.8, 1.3) 0.9 1.1 (0.8, 1.5) 0.7
Ulceration 1.2 (0.9, 1.6) 0.4 1.1 (0.8, 1.5) 0.8
Regression 0.8 (0.5, 1.4) 0.5 0.9 (0.7, 1.2) 0.5
Anatomical location
 Head and neck 1 (referent) 0.002 1 (referent) 0.01
 Upper limb 1.5 (0.9, 2.7) 1.5 (0.6, 3.5)
 Lower limb 2.3 (2.3, 4.0) 1.8 (0.9, 3.6)
 Trunk and genitals 2.4 (0.9, 2.7) 2.5 (1.2, 5.0)
TILs
 Absent 1 (referent) < 0.001 1 (referent) < 0.001
 Non-brisk 0.7 (0.4, 1.1) 0.6 (0.6, 0.6)
 Brisk 0.2 (0.1, 0.5) 0.2 (0.2, 0.3)
Table 4  The risk of recurrent 
melanoma
HR hazard ratio, CI conidence interval
a Multivariable Cox regression with age, Breslow thickness, mitotic rate and NLR modelled as continuous 
variables, whilst other co-variables were handled as categorical variables
Unadjusted risk Adjusteda risk
HR (95% CI) p value HR (95% CI) p value
Host factors
 Neutrophil–lymphocyte ratio 1.1 (1.0, 1.2) 0.2 0.9 (0.7, 1.1) 0.2
 Age 1.0 (1.0, 1.0) 0.008 1.0 (1.0, 1.0) 0.01
Primary tumour factors
 Breslow thickness 1.1 (1.1, 1.2)  < 0.001 1.1 (1.0, 1.3) 0.009
 Ulceration 1.5 (1.1, 2.0) 0.003 1.1 (0.6, 2.0) 0.9
 Mitoses per  mm2 1.0 (1.0, 1.1) < 0.001 1.0 (1.0, 1.0) 0.1
 Angiolymphatic invasion 3.4 (2.1, 5.5) < 0.001 1.4 (0.7, 2.9) 0.4
 Microsatellites 2.5 (1.4, 4.2) 0.001 1.8 (0.4, 4.0) 0.2
 Absence of tumour-iniltrating lymphocytes 4.9 (2.3, 11) < 0.001 5.6 (1.6, 19) 0.008
 Location
  Trunk and genitals 1 (referent) < 0.001 1 (referent) 0.001
  Upper limb 0.7 (0.5, 1.0) 0.5 (0.3, 0.9)
  Lower limb 1.4 (1.1, 1.9) 1.0 (0.6, 1.8)
  Head and neck 1.4 (1.0, 2.1) 2.4 (1.3, 4.5)
Regional node factors
 Sentinel lymph node metastasis 5.8 (4.5, 7.3) < 0.001 5.7 (3.8, 8.5) < 0.001
 Extracapsular spread 1.0 (0.5, 2.0) 0.9 – –
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however, the literature is comparatively sparse in locore-
gional melanoma [34, 37–39]. Of these studies, Lino-Silva 
[38] is the only one to report the association between base-
line NLR and the risk of recurrence. They stated that in 376 
patients a baseline NLR ≥ 2 was associated with a higher risk 
of recurrence (28% versus 22%), although the limitations of 
their sample have already been discussed. Also, this appar-
ent proportional diference was not subject to a hypothesis 
test (and so no efect size was ofered), nor was it adjusted 
for important baseline confounders. These factors might 
explain why it difers to our inding. We add data to this 
important deicit in the literature concerning biomarkers in 
locoregional melanoma and suggest that future researchers 
seek to evaluate the utility of the baseline NLR in a prospec-
tive cohort of individuals with locoregional melanoma, with 
regular repeated measurements (including immediately after 
surgery) to better understand the temporal change of this 
valuable biomarker in melanoma.
The translational value of the NLR in the care of patients 
with melanoma is potentially important because the associa-
tion between NLR and survival from metastatic melanoma 
is unequivocal [52]. The systematic review and meta-regres-
sion by Ding et al. [53] (using data from 12 studies and 
3207 individuals with melanoma) showed that the NLR was 
strongly predictive of overall survival [HR 2.2 (95% CI 1.6, 
3.0)] and disease-free survival [HR 2.2 (95% CI 1.8, 2.7)]. 
Recent data from our group complements this review and 
showed that the baseline NLR was a potentially powerful 
adjunct to SLN biopsy for identifying those individuals at 
the highest risk of death [39] who might beneit most from 
adjuvant therapy. Therefore, as SLN status is the best predic-
tor of survival in melanoma, and survival is strongly associ-
ated with the NLR, our indings and those of prior studies 
[34, 37, 38] suggest that NLR might help to better inform 
treatment choices for patients in the future [19].
Limitations
The retrospective nature of the study meant many of the 
patients did not have a blood test during surveillance, hence 
our nested cohort was only 235 patients and may have been 
underpowered to detect a signiicant diference in NLR. The 
median follow-up for recurrence was only 3.6 years, which 
would capture over 80% of disease recurrences [54] but 
may not identify up to 11% of late melanoma recurrences 
[55]. We quantiied change in biomarkers by comparing the 
pre-operative values to the inal value; however, it is pos-
sible that the NLR may normalise following surgery and 
therefore afect our indings, i.e. if the NLR was abnormal 
preoperatively but regressed to normal following surgery, 
before again rising with recurrence. Our study was subject to 
missing data but the missingness was completely at random, 
so unlikely to bias the outcomes. Future work could measure 
postoperative NLR in addition to pre-operative levels, to 
understand the temporal changes following surgery.
Conclusion
The baseline NLR is associated with the volume of cutane-
ous melanoma at presentation. Further prospective research 
is needed to understand how this personalised biomarker 
changes following surgery for melanoma and whether it may 
also be used for surveillance.
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